Table 3.

Treatment of 132 Hematogenous PJI Episodes

Characteristic	Episodes (n = 132)
Surgical procedure for PJI, No. (%)
No surgerya	3 (2)
Retention of prosthesisb	50 (38)
Removal of prosthesis	79 (60)
Two-stage/multistage exchangec	69 (87)
1-stage exchange	4 (5)
No reimplantation	6 (8)
Median No. of surgeries performed (range)	2 (1–6)
Treatment of primary focus/portal of pathogen entry
No specific interventiond	63 (48)
Antimicrobial treatment only	42 (32)
Surgery	27 (20)
Antimicrobial treatment
Duration of treatment, median (range), wk	15 (3–243)
Duration of intravenous treatment, median (range), wke	4 (1–16)
Duration of oral treatment, median (range), wkf	12 (3–24)
Episodes treated with biofilm-active antibiotics, No. (%)g	72/93 (77)
Episodes treated with antimicrobial suppression, No. (%)h	29/130 (22)

Abbreviation: PJI, periprosthetic joint infection.

Due to hemodynamic instability.

In 46 episodes, mobile implant components were exchanged.

Median interval between ex- and reimplantation (range) was 74 (18–273) days.

Including 39 episodes with unknown focus, 11 episodes after a (para)medical intervention, and 10 episodes that originated from a noninfectious skin lesion. Refusal of further diagnostics/treatment in 3 episodes.

In 129 of 130 episodes with known antimicrobial treatment, intravenous therapy was administered initially.

In 116 of 127 episodes, oral therapy was administered.

That is, rifampin for Staphylococcus sp. or quinolones for gram-negative rods. Thirty-nine episodes were caused by enterococci, streptococci, or Candida spp., for which no biofilm-active treatment is available.

That is, prolonged oral treatment for 30–240 weeks.